Neratinib and the Role of Anti-HER2 Therapy in Salivary Duct Carcinoma

IF 1.5 Q4 ONCOLOGY

Cancer reports Pub Date : 2025-01-15 DOI:10.1002/cnr2.70065

Martina Napolitano, Lucia Trudu, Enrica Martinelli, Chiara Santini, Massimo Dominici, Federica Bertolini

{"title":"Neratinib and the Role of Anti-HER2 Therapy in Salivary Duct Carcinoma","authors":"Martina Napolitano, Lucia Trudu, Enrica Martinelli, Chiara Santini, Massimo Dominici, Federica Bertolini","doi":"10.1002/cnr2.70065","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Backgroud</h3>\n \n <p>Salivary duct carcinoma (SDC) is a rare and aggressive malignancy with a generally dismal prognosis and no standard of care established, despite a known association with epidermal growth factor receptor 2 (HER2) and androgen receptor (AR) over-expression.</p>\n </section>\n \n <section>\n \n <h3> Case</h3>\n \n <p>We report the case of a 64-year-old female with extra- and intracranial metastases of SDC with evidence of AR and HER2 overexpression. After progression on first line chemotherapy, was administered neratinib, a pan-Erb2 receptor tyrosine kinase inhibitor.</p>\n \n <p>Even with central nervous system involvement at diagnosis, a durable clinical response was obtained with a PFS of 11 months and no significant toxicities to manage. Best response observed during tratment was partial response.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>This case confirms the potential efficacy of neratinib in HER2-positive SDC and underlines the need to define the best therapeutic sequence and potential biomarkers for these rare patients.</p>\n </section>\n </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 1","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11735052/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70065","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Backgroud

Salivary duct carcinoma (SDC) is a rare and aggressive malignancy with a generally dismal prognosis and no standard of care established, despite a known association with epidermal growth factor receptor 2 (HER2) and androgen receptor (AR) over-expression.

Case

We report the case of a 64-year-old female with extra- and intracranial metastases of SDC with evidence of AR and HER2 overexpression. After progression on first line chemotherapy, was administered neratinib, a pan-Erb2 receptor tyrosine kinase inhibitor.

Even with central nervous system involvement at diagnosis, a durable clinical response was obtained with a PFS of 11 months and no significant toxicities to manage. Best response observed during tratment was partial response.

Conclusions

This case confirms the potential efficacy of neratinib in HER2-positive SDC and underlines the need to define the best therapeutic sequence and potential biomarkers for these rare patients.

Abstract Image

查看原文本刊更多论文

奈拉替尼和抗her2治疗在唾液管癌中的作用。

背景：涎腺导管癌（SDC）是一种罕见的侵袭性恶性肿瘤，预后一般较差，尽管已知与表皮生长因子受体2 （HER2）和雄激素受体（AR）过表达相关，但目前尚无治疗标准。病例：我们报告一例64岁女性SDC转移灶外和颅内，伴有AR和HER2过表达。在一线化疗进展后，给予奈拉替尼，一种泛erb2受体酪氨酸激酶抑制剂。即使在诊断时中枢神经系统受累，也获得了持久的临床反应，PFS为11个月，没有明显的毒性需要处理。治疗期间观察到的最佳反应为部分反应。结论：该病例证实了neratinib对her2阳性SDC的潜在疗效，并强调了为这些罕见患者确定最佳治疗顺序和潜在生物标志物的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊